Abstract
Objective: Stage II melanoma patients have high risk for regional and distant metastases and may benefit from novel therapeutic strategies. To clarify the role of NK cells in Stage II melanoma, we characterized the cytotoxic activity of NK cells and the expression of various activating and inhibitory receptors in high-risk cutaneous melanoma patients (Stages IIB and IIC) compared to low-risk patients (Stage IA). Materials and Methods: Native and cytokine-treated peripheral blood mononuclear cells were used for functional and phenotypical analyses. Results: Compared to Stage IA-B patients, Stage IIB-C patients showed significantly decreased NK cell activity, as well as decreased expression of the activating NKG2D and CD161 receptors, most likely due to increased serum levels of the immunosuppressive cytokine TGF-β1 in these patients. Interestingly, treatment of periperal blood mononuclear cells with IFN-α, IL-2, IL-12 or the combination of IL-12 and IL-18 significantly induced NK cell activity for both groups of melanoma patients. However, only low-risk patients had a significant increase in the expression of the NKG2D receptor after in vitro treatment with IFN-α, as well as an significant increase in the expression of CD161 after treatment with IFN-α or IL-12. Although IL-2 induced the expression of NKG2D in both groups of patients, this increase was significantly lower in high-risk melanoma. Conclusion: NK cell parameters may be useful as biomarkers of disease progression in localized melanoma patients. Our results further suggest that the use of NK cell-activating cytokines in combination with inhibitors of immunosuppressive factors like TGF-β1 could be a therapeutic option for the treatment of high-risk cutaneous melanoma patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Pahl J, Cerwenka A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology 2017; 222: 11.
Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. Immunol Rev 2006; 214: 130.
Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18: 151.
Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res 2015; 3: 575.
Azzoni L, Zatsepina O, Abebe B, Bennett IM, Kanakaraj P, Perussia B. Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. J Immunol 1998; 161: 3493.
Kirkham CL, Carlyle JR. Complexity and diversity of the NKR-P1:Clr (Klrb1:Clec2) recognition systems. Front Immunol 2014; 5: 214.
Aldemir H, Prod’homme V, Dumaurier MJ, et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 2005; 175: 7791.
Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL. Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 2005; 175: 7796.
Ljunggren HG, Kärre K. In search of the ’missing self’: MHC molecules andNKcell recognition. Immunol Today 1990; 11: 237.
Thielens A, Vivier E, Romagné F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol 2012; 24: 239.
Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc 2006; 81: 500.
Mignogna C, Scali E, Camastra C, et al. Innate immunity in cutaneous melanoma. Clin Exp Dermatol 2017; 42: 243.
Konjević G, Mirjacić Martinović K, Jurisić V, Babović N, Spuzić I. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells. Biomarkers 2009; 14: 258.
Fregni G, Messaoudene M, Fourmentraux-Neves E, et al. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One 2013; 8: e76928.
Mirjačić Martinović KM, Babović NLj, Dzodić RR, Jurišić VB, Tanić NT, Konjević GM. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients. Melanoma Res 2014; 24: 295.
Davey RJ, van der Westhuizen A, Bowden NA. Metastatic melanoma treatment: combining old and new therapies. Crit Rev Oncol Hematol 2016; 98: 242.
Buchbinder EI, McDermott DF. Interferon, interleukin-2 and other cytokines. Hematol Oncol Clin North Am 2014; 28: 571.
Keohane SG, Proby CM, Newlands C, et al. The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K. Br J Dermatol 2018; 179: 824.
Brown RL, Ortaldo JR, Griffith RL, Blanca I, Rabin H. The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free medium. J Immunol Methods 1985; 81: 207.
Jackson A, Warner N. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedmah H, Fahey J, (eds). Manual of Clinical Laboratory Immunology. Washington DC: American Society for Microbiology.
Hayakawa Y. Targeting NKG2D in tumor surveillance. Expert Opin Ther Targets 2012; 16: 587.
Bi J, Tian Z. NK cell exhaustion. Front Immunol 2017; 8: 760.
Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol 2014; 44: 1582.
Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31: 220.
Park YP, Choi SC, Kiesler P, et al. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the ψc cytokines and TGF-β1. Blood 2011; 118: 3019.
Lee JC, Lee KM, Ahn YO, Suh B, Heo DS. A possible mechanism of impaired NK cytotoxicity in cancer patients: down-regulation of DAP10 by TGF-beta1. Tumori 2011; 97: 350.
Lapeyre-Prost A, Terme M, Pernot S, et al. Immunomodulatory activity of VEGF in cancer. Int Rev Cell Mol Biol 2017; 330: 295.
Viac J, Schmitt D, Claudy A. Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma. Cancer Lett 1998; 125: 35.
Pelletier F, Bermont L, Puzenat E, et al. Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol 2005; 152: 685.
Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors 2010; 36: 274.
Terme M, Ullrich E, Aymeric L, et al. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res 2012; 72: 2757.
Tarhini AA, Lorigan P, Leachman S. Operable melanoma: screening, prognostication, and adjuvant and neoadjuvant therapy. Am Soc Clin Oncol Educ Book 2017; 37: 651.
Sanlorenzo M, Vujic I, Carnevale-Schianca F, et al. Role of interferon in melanoma: old hopes and new perspectives. Expert Opin Biol Ther 2017; 17: 475.
Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172: 7335.
Acknowledgments and disclosures
This work was supported by the grants of the Ministry of Education, Science and Technological Development of the Republic of Serbia, numbers III41031 and 175056. We wish to thank Mrs. Jasna Popović Basić and Mrs. Miroslava Ċulafić for excellent technical work and Mrs. Dušica Gavrilović for extensive statistical analyses.
Conflict of Interest: there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Martinović, K.M., Milićević, M., Larsen, A.K. et al. Effect of cytokines on NK cell activity and activating receptor expression in high-risk cutaneous melanoma patients. Eur Cytokine Netw 30, 160–167 (2019). https://doi.org/10.1684/ecn.2019.0440
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/ecn.2019.0440